Inhibikase Therapeutics Inc (NASDAQ: IKT) kicked off on Monday, up 5.19% from the previous trading day, before settling in for the closing price of $1.54. Over the past 52 weeks, IKT has traded in a range of $1.33-$4.20.
During the last 5-year period, the sales growth of Healthcare Sector giant was 18.99%. While this was happening, its average annual earnings per share was recorded 54.02%. With a float of $99.08 million, this company’s outstanding shares have now reached $121.27 million.
Inhibikase Therapeutics Inc (IKT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Inhibikase Therapeutics Inc is 18.30%, while institutional ownership is 36.32%. The most recent insider transaction that took place on Nov 21 ’25, was worth 2,999,999. In this transaction 10% Owner of this company bought 2,068,965 shares at a rate of $1.45, taking the stock ownership to the 13,018,965 shares.
Inhibikase Therapeutics Inc (IKT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 54.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.28% during the next five years compared to 18.99% growth over the previous five years of trading.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Trading Performance Indicators
Take a look at Inhibikase Therapeutics Inc’s (IKT) current performance indicators. Last quarter, stock had a quick ratio of 11.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.70 in one year’s time.
Technical Analysis of Inhibikase Therapeutics Inc (IKT)
Looking closely at Inhibikase Therapeutics Inc (NASDAQ: IKT), its last 5-days average volume was 0.51 million, which is a jump from its year-to-date volume of 0.2 million. As of the previous 9 days, the stock’s Stochastic %D was 81.29%.
During the past 100 days, Inhibikase Therapeutics Inc’s (IKT) raw stochastic average was set at 50.88%, which indicates a significant decrease from 88.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0956 in the past 14 days, which was lower than the 0.1216 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5493, while its 200-day Moving Average is $1.8113. However, in the short run, Inhibikase Therapeutics Inc’s stock first resistance to watch stands at $1.6717. Second resistance stands at $1.7233. The third major resistance level sits at $1.7967. If the price goes on to break the first support level at $1.5467, it is likely to go to the next support level at $1.4733. Should the price break the second support level, the third support level stands at $1.4217.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Key Stats
The company with the Market Capitalisation of 196.45 million has total of 75,175K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -27,520 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -11,930 K.
